Actilyse IV Infusion 50 mg/50 ml

Actilyse IV Infusion is a life-saving thrombolytic medication containing Alteplase (50 mg/50 ml) manufactured by Boehringer Ingelheim. Priced at ৳50,000.00 per vial, this IV Infusion is primarily used for treating acute ischemic stroke, myocardial infarction, and pulmonary embolism by dissolving blood clots.

This medication works through fibrin-specific plasminogen activation, targeting clots while minimizing systemic bleeding risks. The pharmacokinetics show rapid plasma clearance (380-570 mL/min) with hepatic metabolism. Clinical trials report 11% patients experienced fibrinogen levels below 100 mg/dL at 1.25 mg/kg doses.

Dosage guidelines vary by condition:

• Stroke: 0.9 mg/kg within 3 hours of symptoms
• Heart attack: Up to 100 mg via accelerated/3-hour infusion
• Pulmonary embolism: 100 mg over 2 hours

Strict blood pressure monitoring is required during stroke treatment.

Common side effects include bleeding complications (39% in trials), orolingual angioedema (particularly with ACE inhibitors), and cholesterol embolization. The drug carries Pregnancy Category C status, with embryocidal effects observed in animal studies at higher doses.

Store lyophilized vials below 30°C or refrigerated (2-8°C). Reconstituted solutions remain stable for 8 hours. Avoid concurrent use with anticoagulants due to bleeding risks. For alternatives, explore other fibrinolytic agents under medical supervision.

Stroke: 0.9 mg/kg (max 90 mg) within 3 hrs of onset – 10% as IV bolus, remainder over 60 mins. AMI: Up to 100 mg based on weight. PE: 100 mg over 2 hrs. Monitor BP continuously. Discontinue if INR >1.7.

The following adverse reactions are:

• Bleeding 
• Orolingual Angioedema 
• Cholesterol Embolization
• Reembolization of Deep Venous Thrombi during Treatment for Acute Massive Pulmonary
• Embolism.

Pregnancy Category C. Use only if potential benefit justifies risk. Breastfeeding not recommended during therapy.

Monitor for bleeding every 15 mins. Avoid IM injections. Discontinue immediately if angioedema occurs. Watch for cholesterol embolism signs.

Not approved for pediatrics. Elderly (>77 yrs) have higher ICH risk. Dose adjustment may needed in hepatic/renal impairment.